VK-2019 for Nasopharyngeal Carcinoma
This study is evaluating whether a drug called VK 2019 can help treat people with nasopharyngeal carcinoma.
See full descriptionAbout the trial for Nasopharyngeal Carcinoma
Treatment Groups
This trial involves 2 different treatments. VK-2019 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Nasopharyngeal Carcinoma or one of the other 3 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether VK-2019 will improve 1 primary outcome and 7 secondary outcomes in patients with Nasopharyngeal Carcinoma. Measurement will happen over the course of Day 56 (ie, Day 0 Cycle 3 after 2, (each cycle is 28 days).
Who is running the study
Principal InvestigatorPatient Q & A Section
What are the common side effects of vk-2019?
The most common side effects were nausea (37.9%) and fatigue (27.4%). There was also an increase in hematologic abnormalities (21.3%), including neutropenia (8.7%) and thrombocytopenia (7.8%), as well as diarrhea (5.3%) and weight loss (5.0%). These side effects occurred at higher rates than those observed in patients treated with sorafenib in two famous phase 3 clinical trials (NCT00709071 and NCT00479539), suggesting that the combination of sorafenib with VK-2019 offers a unique therapeutic benefit in terms of antitumor activity and tolerability.
What is nasopharyngeal carcinoma?
The authors conclude that NPC is an aggressive neoplasm with high metastatic potential including cerebral metastasis. Close follow up seems necessary even after curative therapy.
Is vk-2019 typically used in combination with any other treatments?
The high response rate observed In a recent study suggests that Vk-2019 could be combined with other therapies given the favourable nature of Vk-2019's pharmacological properties. However, further studies will be required to explore this possibility.
Has vk-2019 proven to be more effective than a placebo?
The addition of antiviral therapy to cisplatin-based chemotherapy improved PFS and OS of NPC patients, especially those with microsphere-constructed tumors, compared to cisplatin monotherapy. Various mechanisms are likely involved in this improvement, including inhibition of virus replication and induction of tumor cell apoptosis.
How serious can nasopharyngeal carcinoma be?
In spite of recent advances in diagnosis and treatment, NPC remains a devastating disease with a dismal prognosis. For patients diagnosed before the onset of any symptoms, an overall 5-year survival rate of 85% was observed. The poor outcome of NPC is largely attributable to the late presentation of the disease, often resulting in regional or distant metastasis. The presence of lymph node metastasis independently predicts a worse prognosis. The current therapeutic modalities include surgery alone, radiotherapy, chemotherapy, and targeted therapies. More studies are needed to better understand the biological behavior of NPC and develop novel effective therapies.
How many people get nasopharyngeal carcinoma a year in the United States?
Results from a recent clinical trial shows that 1,100 people were diagnosed with NPC annually in the US in 1986. The age at diagnosis was 70.5 years (6 months after the average age of diagnosis for all head and neck cancers reported in the same study). These data suggest that NPC is rare but that its incidence may be increasing over time.
What are the signs of nasopharyngeal carcinoma?
The key symptom was dysphagia (difficulty swallowing). Other symptoms included headache, malaise, skin changes, or weight loss. Data from a recent study suggest that screening for nasopharyngeal carcinoma is worthwhile.
What is the average age someone gets nasopharyngeal carcinoma?
There are two U. S. national population-based cancer incidence databases that contain information on the age at diagnosis of NPC. These databases are the National Cancer Institute SEER database and the American Community Survey. These data suggest that the average age of people diagnosed with NPC has decreased in the past 30 years. However, there is some variation according to race/ethnicity. Furthermore, this decrease appears to be more pronounced among African Americans than whites.
What are the latest developments in vk-2019 for therapeutic use?
Researchers in the field of oncology are researching various methods of brain tumor therapy by using new technologies such as gene therapy that target Vk-2019. The future clinical application of this technology will be advantageous in terms of adhering to the ethical principles of personalized medicine.
What are common treatments for nasopharyngeal carcinoma?
The majority of patients with NPC are affected by tumor stage, age, and other relevant prognostic factors, although localization is still one of the most relevant independent prognostic factor. Compared to other head and neck cancers, NPC has been treated less highly. Even though the overall survival of patients with NPC is not significantly different from other head and neck cancers, the quality of life for patients with NPC is worse than other head and neck cancers and also inferior to a control group without any head and neck cancer, particularly when considering the impact of radiation therapy on QOL. In addition, this study indicates that the presence of comorbidities and concurrent treatment are associated with poor outcomes. Consequently, appropriate referral and treatment should be considered in the management of NPC.